ClinicalTrials.gg
CompletedNCT04508621RALLYUpdated Dec 18, 2023Results posted

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

A Phase 3 interventional study of TNX-102 SL and Placebo SL Tablet in Fibromyalgia, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 36 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-18.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
514
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Enrollment
24th of 320
514 · median 72
Started
2020
with 13 others
Phase 3
55 of 369
2 open now
Registered
277th of 369
by date
Lead sponsor
8 of 369
Tonix Pharmaceuticals, Inc.

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 24th largest by enrollment of the 320 interventional ones that give a count, is one of 14 that started in 2020, is one of 55 in phase 3, and was the 277th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.

03

Conditions studied

  • Fibromyalgia

Keywords

  • Pain
  • Sleep
  • Fibromyalgia
  • FM
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is male or female 18 to 65 years of age, inclusive.
  • The patient has a diagnosis of primary FM as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary Diagnostic Criteria)
  • The in clinic 7-day recall NRS average daily pain intensity score at Screening Visit within protocol defined range.

Exclusion criteria

Exclusion Criteria:

  • History of or evidence for a diagnosis of borderline personality disorder (BPD).
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
514 participants (actual)

Study arms

  • Experimental
    TNX-102 SL Tablet, 5.6 mg

    1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.

    Drug: TNX-102 SL

  • Placebo comparator
    Placebo SL Tablet

    1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.

    Drug: Placebo SL Tablet

Interventions

  • Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.

    Also known as: Low dose cyclobenzaprine sublingual tablets

  • DrugPlacebo SL Tablet

    Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.

    Also known as: Placebo sublingual tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.

    Patients provide a daily numeric assessment of their average pain (24-hour recall), via an electronic diary, using an 11-point NRS. Scores range from 0 (no pain) to 10 (worst possible pain).

    Time frame: 14 weeks

Secondary outcomes

  1. Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved"

    The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.

    Time frame: 14 weeks

  2. Change From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score.

    The FIQ-R is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.

    Time frame: 14 weeks

  3. Change From Baseline to Week 14 in the FIQ-R Function Domain Score

    The FIQ-R is a validated questionnaire. Score on the function domain range from 0 to 90 where a higher score means worse outcome.

    Time frame: 14 weeks

  4. Change From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance

    The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.

    Time frame: 14 weeks

  5. Change From Baseline to Week 14 in the PROMIS Score for Fatigue

    The PROMIS fatigue short form 8a consist of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.

    Time frame: 14 weeks

  6. Change From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality

    Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).

    Time frame: 14 weeks

07

Results

Posted Dec 2, 2022
Limitations and caveats
Recruitment during COVID-19 pandemic

Participant flow

Participant flow — Overall Study
MilestoneTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Started256258
Completed189210
Not completed6748
Withdrew: Adverse event3916
Withdrew: Lack of efficacy28
Withdrew: Physician decision01
Withdrew: Withdrawal by subject1014
Withdrew: Lost to follow-up129
Withdrew: Covid-19 related crisis30
Withdrew: Subject non-compliance10

Outcome measures

PrimaryChange From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.

Patients provide a daily numeric assessment of their average pain (24-hour recall), via an electronic diary, using an 11-point NRS. Scores range from 0 (no pain) to 10 (worst possible pain).

Time frame:
14 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.
score on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.-1.6 (-1.8 to -1.3)-1.3 (-1.5 to -1.1)
Statistical analysis
  • TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet · Mixed Model Repeated Measures · p = 0.115 · Ls mean difference: -0.2 · 95% CI -0.6 to 0.1Treatment difference = TNX-102 SL - Placebo
SecondaryNumber of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved"

The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.

Time frame:
14 weeks
Reported as:
Count of participants · Participants
Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved"
ParticipantsTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved"7656
Statistical analysis
  • TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet · Pearson Chi-Squared · p = 0.038 · Difference in proportions: 8.0 · 95% CI 0.5 to 15.5
SecondaryChange From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score.

The FIQ-R is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.

Time frame:
14 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score.
score on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score.-15.3 (-17.6 to -13.1)-12.0 (-14.2 to -9.8)
Statistical analysis
  • TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet · Mixed Model Repeated Measures · p = 0.030 · Ls mean difference: -3.4 · 95% CI -6.4 to -0.3Treatment difference = TNX-102 SL - Placebo
SecondaryChange From Baseline to Week 14 in the FIQ-R Function Domain Score

The FIQ-R is a validated questionnaire. Score on the function domain range from 0 to 90 where a higher score means worse outcome.

Time frame:
14 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 14 in the FIQ-R Function Domain Score
score on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline to Week 14 in the FIQ-R Function Domain Score-8.8 (-10.9 to -6.7)-8.4 (-10.5 to -6.4)
Statistical analysis
  • TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet · Mixed Model Repeated Measures · p = 0.797 · Ls mean difference: -0.4 · 95% CI -3.2 to 2.5Treatment Difference = TNX-102 SL - Placebo
SecondaryChange From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance

The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.

Time frame:
14 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance
score on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance-7.4 (-8.6 to -6.2)-5.1 (-6.2 to -4.0)
Statistical analysis
  • TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet · Mixed Model Repeated Measures · p = 0.004 · Ls mean difference: -2.3 · 95% CI -3.8 to -0.7Treatment Difference = TNX-102 SL - Placebo
SecondaryChange From Baseline to Week 14 in the PROMIS Score for Fatigue

The PROMIS fatigue short form 8a consist of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40.

Time frame:
14 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 14 in the PROMIS Score for Fatigue
score on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline to Week 14 in the PROMIS Score for Fatigue-6.6 (-7.7 to -5.5)-5.4 (-6.4 to -4.3)
Statistical analysis
  • TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet · Mixed Model Repeated Measures · p = 0.101 · Ls mean difference: -1.2 · 95% CI -2.7 to 0.2Treatment Difference = TNX-102 SL - Placebo
SecondaryChange From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality

Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).

Time frame:
14 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality
score on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality-1.5 (-1.7 to -1.3)-1.3 (-1.5 to -1.0)
Statistical analysis
  • TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet · Mixed Model Repeated Measures · p = 0.094 · Ls mean difference: -0.3 · 95% CI -0.6 to 0.0Treatment Difference = TNX-102 SL - Placebo

Adverse events

Collected over 14 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TNX-102 SL Tablet, 5.6 mg0/256 (0%)6/256 (2.3%)80/256 (31.3%)
Placebo SL Tablet0/258 (0%)0/258 (0%)5/258 (1.9%)
Most frequent serious events
Most frequent serious events
EventTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
COVID-19 pneumoniaInfections and infestations1/2560/258
Localized infectionInfections and infestations1/2560/258
PneumoniaInfections and infestations1/2560/258
PancreatitisGastrointestinal disorders1/2560/258
Bile duct stoneHepatobiliary disorders1/2560/258
Forearm fractureInjury, poisoning and procedural complications1/2560/258
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2560/258
Most frequent other events
Most frequent other events
EventTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Hypoaesthesia oralGastrointestinal disorders72/2562/258
Product taste abnormalProduct Issues26/2562/258
Oral discomfortGastrointestinal disorders23/2562/258
Tongue discomfortGastrointestinal disorders16/2562/258

Baseline characteristics

Age, Continuous
Age, Continuous(years)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
Mean48.9 ± 10.5548.5 ± 10.6048.7 ± 10.57
Sex: Female, Male
Sex: Female, Male(Participants)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
Female242245487
Male141327
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
American Indian or Alaska Native202
Asian516
Native Hawaiian or Other Pacific Islander033
Black or African American162440
White226223449
More than one race6612
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
United States256258514
08

Study locations

36 sites
  • Tonix Clinical Site
    Birmingham, Alabama 35216, United States
  • Tonix Clinical Site
    Phoenix, Arizona 85016, United States
  • Tonix Clinical Site
    Oceanside, California 92056, United States
  • Tonix Clinical Site
    San Diego, California 92103, United States
  • Tonix Clinical Site
    Santa Ana, California 92705, United States
  • Tonix Clinical Site
    Temecula, California 32591, United States
  • Tonix Clinical Site
    Cromwell, Connecticut 06416, United States
  • Tonix Clinical Site
    Fort Myers, Florida 33912, United States
  • Tonix Clinical Site
    Jacksonville, Florida 32256, United States
  • Tonix Clinical Site
    North Miami, Florida 33161, United States
  • Tonix Clinical Site
    Ocala, Florida 34470, United States
  • Tonix Clinical Site
    Orlando, Florida 32801, United States
  • Tonix Clinical Site
    Alpharetta, Georgia 30022, United States
  • Tonix Clinical Site
    Evansville, Indiana 47714, United States
  • Tonix Clinical Site
    West Des Moines, Iowa 50265, United States
  • Tonix Clinical Site
    Prairie Village, Kansas 66208, United States
  • Tonix Clinical Site
    New Orleans, Louisiana 70115, United States
  • Tonix Clinical Site
    Boston, Massachusetts 02131, United States
  • Tonix Clinical Site
    Albuquerque, New Mexico 87109, United States
  • Tonix Clinical Site
    Williamsville, New York 14221, United States
  • Tonix Clinical Site
    High Point, North Carolina 27262, United States
  • Tonix Clinical Site
    Raleigh, North Carolina 27612, United States
  • Tonix Clinical Site
    Cincinnati, Ohio 45219, United States
  • Tonix Clinical Site
    Dayton, Ohio 45417, United States
  • Tonix Clinical Site
    North Canton, Ohio 44720, United States
  • Tonix Clinical Site
    Oklahoma City, Oklahoma 73112, United States
  • Tonix Clinical Site
    Tulsa, Oklahoma 74133, United States
  • Tonix Clinical Site
    Portland, Oregon 97210, United States
  • Tonix Clinical Site
    Warwick, Rhode Island 02886, United States
  • Tonix Clinical Site
    Chattanooga, Tennessee 37421, United States
  • Tonix Clinical Site
    Memphis, Tennessee 38119, United States
  • Tonix Clinical Site
    Austin, Texas 78737, United States
  • Tonix Clinical Site
    Dallas, Texas 75231, United States
  • Tonix Clinical Site
    Salt Lake City, Utah 84102, United States
  • Tonix Clinical Site
    Charlottesville, Virginia 22911, United States
  • Tonix Clinical Site
    Kenosha, Wisconsin 53144, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Nov 2021, 15 months.

Results were first posted in Dec 2022, 1 year 1 month after primary completion.

Of 17 phase 3 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2020
First posted
Aug 11, 2020
StartActual
Jul 22, 2020
Primary completionActual
Nov 1, 2021
CompletionActual
Nov 1, 2021
Results first posted
Dec 2, 2022
Last update
Dec 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04508621
Responsible party
Sponsor
First posted
Aug 11, 2020
Start date
Jul 22, 2020
Primary completion
Nov 1, 2021
Completion
Nov 1, 2021
Results posted
Dec 2, 2022
Last update
Dec 18, 2023

Study contacts

Gregory Sullivan, MD
study director · Tonix Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion